Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01949454
Other study ID # SF1707/UND
Secondary ID
Status Completed
Phase N/A
First received September 19, 2013
Last updated April 20, 2016
Start date November 2013
Est. completion date April 2016

Study information

Verified date April 2016
Source University of Pennsylvania
Contact n/a
Is FDA regulated No
Health authority Ethiopia: National Research Ethics Review Committee (NRERC), Ministry of Science and TechnologyEthiopia: Food, Medicine and Health Care Administration and Control Authority of Ethiopia
Study type Interventional

Clinical Trial Summary

The investigators aim to evaluate a new potentially cost-effective approach to improving trichiasis surgery outcomes, perioperative topical anti-inflammatory therapy. The investigators hypothesize that adjunctive topical fluorometholone therapy following trichiasis surgery will reduce the risk of recurrent trichiasis. The rationale for this hypothesis is that interruption of inflammation postoperatively would reduce postoperative scarring, leading to better outcomes. As an initial step toward evaluating this modality, the investigators believe it to be necessary to evaluate topical corticosteroid therapy in a safety-oriented study, for which the investigators also hypothesize that fluorometholone will have a perioperative safety profile acceptable for large-scale programmatic use. Topical corticosteroid therapy is associated with potential risks of cataract induction and intraocular pressure (IOP) elevation in susceptible individuals. Fluorometholone has lower intraocular penetration than alternative corticosteroids, with correspondingly less IOP-raising effect while still having favorable effects on conjunctival inflammation, and is a low-cost generic drug. Its poor delivery of corticosteroid into the eye itself provides an advantage in this setting, as the major side effects of therapy are the result of intraocular effects, and therapy only is needed to the conjunctiva. However, prior to use in a large-scale trial it is sensible to make sure adverse outcomes are not observed in a substantial number of TT patients in a smaller scale trial. Secondary goals of such a trial are to evaluate alternative topical corticosteroid dosing schedules to identify an optimal dosing schedule and to identify any preliminary signals of potential efficacy.


Description:

Protocol Title: Fluorometholone 0.1% as Perioperative Adjunct Therapy for Lid-rotation Surgery in Trachomatous Entropion and Trichiasis, Dose-varying Study

Study Design: Randomized, double-masked, dose-ranging study of three dose levels of fluorometholone 0.1% or placebo in one eye of subjects with trachomatous trichiasis (TT) undergoing lid rotation surgery

Primary Study Objective: Evaluate the safety and tolerability of three (3) doses of fluorometholone 0.1% in subjects with trachomatous trichiasis (TT) undergoing lid rotation surgery (Bilamellar Tarsal Rotation)

Secondary Study Objective: Conduct a preliminary assessment of the efficacy of three (3) doses of fluorometholone 0.1% in subjects with trachomatous trichiasis (TT) undergoing lid rotation surgery (Bilamellar Tarsal Rotation)

Number of Subjects: Up to 156 eyes of up to 156 subjects

Study Population: Subjects with trachomatous trichiasis (TT) undergoing lid rotation surgery (Bilamellar Tarsal Rotation)

Test Articles:

1. Fluorometholone 0.1% one drop twice daily for four weeks

2. Placebo one drop twice daily for four weeks

3. Fluorometholone 0.1% one drop four times daily for four weeks

4. Placebo one drop four times daily for four weeks

5. Fluorometholone 0.1% one drop four times daily for eight weeks

6. Placebo one drop four times daily for eight weeks

Visit Schedule: Following trichiasis surgery on Day 0, subjects will return for study visits approximately on Days 14, 28, 56, 90, and 365

Tolerability Parameters:

- Treatment-emergent ocular symptoms/signs

- Discontinuation of drug / treatment because of side effects

Safety Parameters:

- Intraocular pressure elevation ≥30 mm Hg

- Cataract

- Adverse events

- Treatment emergent abnormal ophthalmic findings

- Treatment emergent external examination findings

- Visual acuity

Efficacy Parameters:

- Trichiasis recurrence

- Entropion recurrence

- Trachoma activity grade (to the extent activity can be graded in eyes with severe trachomatous scarring)


Recruitment information / eligibility

Status Completed
Enrollment 154
Est. completion date April 2016
Est. primary completion date April 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Age 18 years or more

2. Diagnosis with trachomatous trichiasis

3. Plan for lid rotation surgery (Bilamellar Tarsal Rotation) on at least one upper eyelid

4. LOCS 3 cataract grading is level 3 or less for the nuclear cataract scale, and level 2 or less for the cortical cataract and posterior subcapsular cataract scales.

5. Intraocular pressure between 8-20 mm Hg in the study eye.

Exclusion Criteria:

1. Contraindications to the use of the test articles

2. Known allergy or sensitivity to any medication used in this study, including the study medication or its components (e.g., fluorometholone)

3. Currently taking more than two ocular anti-hypertensive medications in the study eye (prior IOP-lowering surgery is acceptable; combinations of two agents such as Cosopt and Combigan are considered two medications)

4. Glaucoma sufficiently advanced that an intraocular pressure spike potentially would put the patient at substantial risk of vision loss, per study ophthalmologist's judgment.

5. Non-phakic (i.e., pseudophakic or aphakic) study eye (contralateral non-phakic eye is permitted).

6. Other than trachoma, any active ocular infections (bacterial, viral, or fungal), or any active ocular inflammation (e.g., scleritis, iritis).

7. History or diagnosis of ocular herpes or presence of a corneal lesion of suspected herpetic origin; or a diagnosis or suspected diagnosis of ophthalmic mycobacterial infection in either eye.

8. Corneal or scleral thinning in either eye.

9. A severe / serious ocular pathology or medical condition which may preclude study completion.

10. Any condition for which it is anticipated ocular or systemic corticosteroid therapy would be required.

11. Unwilling to discontinue use of contact lenses for the duration of the study (should the unusual circumstance of a trachomatous trichiasis patient who uses contact lenses be encountered)

12. Any significant illness or condition that could, in the investigator's or sub-investigator's opinion, be expected to interfere with the study parameters or study conduct; or put the subject at significant risk

13. For women of childbearing age, currently pregnant and/or breastfeeding, as obtained by self-report (because of concerns about the (programmatic) use of azithromycin in this setting).

14. Cataract in the study eye, defined as LOCS-3 cataract grading is level 3.1 or more for the nuclear cataract scale, or level 2.1 or more for the cortical cataract or posterior subcapsular cataract scales.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Fluorometholone 0.1% ophthalmic solution

Other:
Artificial tears (Placebo)
Artificial tears (Placebo)

Locations

Country Name City State
Ethiopia Grarbet Tehadiso Mahber (Grarbet Hospital) Butajira Snnpr

Sponsors (4)

Lead Sponsor Collaborator
University of Pennsylvania Berhan Public Health and Eye Care Consultancy PLC, Grarbet Tehadiso Mahber, Lions Clubs International Foundation (funding)

Country where clinical trial is conducted

Ethiopia, 

Outcome

Type Measure Description Time frame Safety issue
Other Treatment-emergent ocular symptoms/signs Within the period of randomized treatment (either 4 or 8 weeks from randomization) Within 4-8 weeks Yes
Other Discontinuation of drug / treatment because of side effects During the period of treatment (either 4 or 8 weeks after randomization) Within 4-8 weeks of randomization Yes
Other Other adverse events Within 1 year Yes
Other Visual acuity Changes from baseline. Changes could either be favorable or unfavorable. Within 1 year Yes
Other Entropion recurrence Among cases with entropion at baseline, the incidence of entropion recurrence. Within 1 year No
Other Trachoma activity grade WHO trachoma activity grade (to the extent activity can be graded in eyes with severe trachomatous scarring) Within 1 year No
Primary Safety assessments Incident cataract is defined as either: 1) a two-step worsening on the nuclear, cortical, and/or posterior subcapsular LOCS-3 scale; or 2) undergoing cataract surgery prior to that point in follow-up.
Intraocular pressure elevation
Other dose-limiting toxicity: 1) SAEs (see below) judged as likely related to the treatment by the investigators; 2) vision-threatening non-trachoma infections, e.g., corneal ulcer; 3) anaphylaxis or other events requiring immediate resuscitation; or 4) when the clinician-investigators determine that other AEs observed in a subject would make future applications of the treatment contraindicated on the basis of side effects.
Within one year of randomization Yes
Secondary Recurrence of trichiasis in the study eye Lashes touching the globe or cornea Within one year of randomization No
See also
  Status Clinical Trial Phase
Completed NCT03676140 - Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Phase 3
Completed NCT01202331 - Tripartite International Research for the Elimination of Trachoma Phase 4
Completed NCT05634759 - Enhancing the A in SAFE for Trachoma Phase 4
Recruiting NCT04185402 - Azithromycin Reduction to Reach Elimination of Trachoma Phase 4
Active, not recruiting NCT00886015 - Modified Instrumentation for Surgery to Correct Trichiasis Phase 3
Completed NCT00792922 - Partnership for Rapid Elimination of Trachoma Phase 4
Completed NCT00522860 - A Trial of Non-absorbable Versus Absorbable Sutures for Trichiasis Surgery Phase 4
Completed NCT00221364 - Trachoma Elimination Follow-up Phase 4
Completed NCT00322972 - Trachoma Amelioration in Northern Amhara (TANA) Phase 4
Withdrawn NCT00286026 - Azithromycin in Control of Trachoma II Phase 4
Completed NCT00347763 - Effect of Intensive Fly Control on Trachoma and Ocular Chlamydia Infection in Tanzania Phase 4
Terminated NCT04002726 - App-based Versus Slide-based Inter-grader Agreement (IGA) Test for Trachoma Graders N/A
Terminated NCT03997487 - Smartphone App for Taking Images of Conjunctivae N/A
Not yet recruiting NCT06289647 - Azithromycin Reduction to Reach Elimination of Trachoma B Phase 4
Withdrawn NCT02655432 - Performance of a Photoscreener for Vision Screening in a Haitian Pediatric Population Phase 0
Completed NCT01767506 - A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial N/A
Completed NCT00618449 - Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger Phase 4
Completed NCT00356720 - Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% Versus Oral Azithromycin in Treatment of Trachoma Phase 3
Completed NCT03813069 - Testing Insect Repellents Against Musca Sorbens, the Vector of Trachoma Phase 2
Recruiting NCT03335072 - Kebele Elimination of Trachoma for Ocular Health Phase 4